Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SRC014
MIFTS: 66

Sarcoma

Categories: Bone diseases, Cancer diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Sarcoma

About this section

MalaCards integrated aliases for Sarcoma:

Name: Sarcoma 12 29 54 6 15 17 71
Connective and Soft Tissue Neoplasm 12
Tumor of Soft Tissue and Skeleton 12
Sarcoma - Category 71
Sarcomas 15

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Bone diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:1115
ICD9CM 34 171 171.9
SNOMED-CT 67 93765001
ICD10 32 C49
UMLS 71 C0153519 C1261473 C1299262
Sources

Summaries for Sarcoma

About this section
Disease Ontology : 12 A cell type cancer that has material basis in abnormally proliferating cells derives from embryonic mesoderm.

MalaCards based summary : Sarcoma, also known as connective and soft tissue neoplasm, is related to ewing sarcoma and sarcoma, synovial. An important gene associated with Sarcoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Lopinavir and Lamivudine have been mentioned in the context of this disorder. Affiliated tissues include bone, lung and myeloid, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 A sarcoma is a cancer that arises from transformed cells of mesenchymal (connective tissue) origin.... more...

Sources

Related Diseases for Sarcoma

About this section

Diseases related to Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2127)
# Related Disease Score Top Affiliating Genes
1 ewing sarcoma 35.6 TP53 SSX1 KIT FLI1 EWSR1
2 sarcoma, synovial 35.6 SSX2 SSX1 KIT FLI1 EWSR1
3 undifferentiated pleomorphic sarcoma 35.2 PIK3CA KRAS KIT
4 retroperitoneal sarcoma 35.0 SSX2 KIT EWSR1
5 esophagus sarcoma 34.8 SSX2 KIT
6 biphasic synovial sarcoma 34.8 SSX2 SSX1 EWSR1
7 li-fraumeni syndrome 34.8 TP53 RB1 KRAS HRAS CHEK2
8 epithelioid cell synovial sarcoma 34.8 SSX2 SSX1 EWSR1
9 osteogenic sarcoma 34.7 TP53 RB1 JUN HOTAIR FAU CHEK2
10 heart sarcoma 34.5 SSX2 SSX1
11 spindle cell synovial sarcoma 34.5 SSX2 SSX1
12 lung sarcoma 34.5 SSX2 SSX1
13 rhabdoid cancer 34.2 TP53 SSX2 EWSR1
14 uterine carcinosarcoma 34.1 TP53 RB1 PIK3CA KRAS KIT HRAS
15 rhabdomyosarcoma 34.1 TP53 SSX2 SSX1 RB1 KRAS KIT
16 fibrosarcoma 33.8 TP53 SSX2 SSX1 KIT JUN EWSR1
17 liposarcoma 33.8 TP53 RB1 PIK3CA JUN EWSR1
18 gastrointestinal stromal tumor 33.8 TP53 KRAS KIT HOTAIR BRAF
19 myxoid liposarcoma 33.8 TP53 SSX2 SSX1 EWSR1
20 muscle cancer 33.7 TP53 SSX2 SSX1 KIT HRAS EWSR1
21 chondrosarcoma, extraskeletal myxoid 33.7 SSX2 SSX1 KIT EWSR1
22 angiosarcoma 33.6 TP53 KRAS KIT FLI1
23 carcinosarcoma 33.6 TP53 PIK3CA KRAS KIT HRAS
24 hemangiopericytoma, malignant 33.6 SSX2 SSX1 KIT
25 embryonal rhabdomyosarcoma 33.5 TP53 HRAS EWSR1
26 rhabdomyosarcoma 2 33.5 TP53 SSX2 SSX1 EWSR1
27 wilms tumor 1 33.5 TP53 KRAS KIT HRAS EWSR1 CHEK2
28 neurofibrosarcoma 33.4 TP53 KIT FES
29 histiocytoma 32.6 TP53 KIT EWSR1
30 lymphoma 32.6 TP53 RB1 PIK3CA KIT CHEK2 BRAF
31 myeloid leukemia 32.6 TP53 LYN KRAS KIT HRAS FES
32 mesenchymal cell neoplasm 32.4 TP53 SSX2 KIT EWSR1
33 adenocarcinoma 32.1 TP53 RB1 PIK3CA KRAS KIT HRAS
34 neurofibromatosis, type iv, of riccardi 32.1 TP53 KRAS KIT HRAS
35 glioblastoma multiforme 32.0 TP53 SRC RB1 PIK3CA KRAS KIT
36 leukemia, acute myeloid 32.0 TP53 SRC LYN KRAS KIT JUN
37 hemangioma 32.0 TP53 KRAS KIT FLI1
38 leukemia, acute lymphoblastic 31.9 RB1 LYN KRAS KIT JUN HRAS
39 extraosseous chondrosarcoma 31.9 SSX2 SSX1 EWSR1
40 leukemia 31.8 TP53 RB1 KRAS KIT HRAS HOTAIR
41 adenoma 31.8 TP53 PIK3CA KRAS BRAF
42 leukemia, chronic lymphocytic 31.8 TP53 SRC LYN KRAS KIT HRAS
43 exanthem 31.8 KRAS KIT HRAS
44 cellular myxoid liposarcoma 31.7 SSX2 SSX1 PIK3CA KIT EWSR1
45 thyroid carcinoma 31.7 TP53 PIK3CA HRAS BRAF
46 neuroblastoma 31.7 TP53 SRC RB1 PIK3CA LYN KIT
47 acute promyelocytic leukemia 31.7 SRC RB1 LYN KRAS JUN HRAS
48 thymoma 31.7 TP53 PIK3CA KIT HRAS
49 t-cell leukemia 31.7 TP53 RB1 PIK3CA KRAS JUN HRAS
50 myelofibrosis 31.7 TP53 SRC LYN KIT HRAS

Graphical network of the top 20 diseases related to Sarcoma:



Diseases related to Sarcoma
Sources

Symptoms & Phenotypes for Sarcoma

About this section

GenomeRNAi Phenotypes related to Sarcoma according to GeneCards Suite gene sharing:

26 (show all 18)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.76 HRAS KRAS PIK3CA BRAF
2 Decreased viability GR00106-A-0 10.76 KRAS
3 Decreased viability GR00221-A-1 10.76 HRAS KRAS PIK3CA KIT
4 Decreased viability GR00221-A-2 10.76 CHEK2 HRAS JUN KRAS PIK3CA
5 Decreased viability GR00221-A-3 10.76 CHEK2 HRAS JUN
6 Decreased viability GR00221-A-4 10.76 CHEK2 PIK3CA BRAF
7 Decreased viability GR00301-A 10.76 KRAS BRAF KIT SRC
8 Decreased viability GR00342-S-2 10.76 CHEK2
9 Decreased viability GR00381-A-1 10.76 KRAS BRAF
10 Decreased viability GR00402-S-2 10.76 CHEK2 HRAS JUN KRAS PIK3CA BRAF
11 Decreased substrate adherent cell growth GR00193-A-1 9.87 KIT
12 Decreased substrate adherent cell growth GR00193-A-2 9.87 KIT
13 Decreased substrate adherent cell growth GR00193-A-3 9.87 BRAF CHEK2
14 Decreased substrate adherent cell growth GR00193-A-4 9.87 BRAF CHEK2 KIT
15 Decreased cell migration GR00055-A-1 9.85 BRAF FES HRAS KRAS LYN PIK3CA
16 Decreased viability in esophageal squamous lineage GR00235-A 9.85 BRAF CHEK2 HRAS JUN KIT KRAS
17 Decreased viability in HMC1.1 cells GR00105-A-0 9.13 KIT LYN SRC
18 Increased cell migration GR00055-A-3 9.02 BRAF HRAS KRAS LYN PIK3CA

MGI Mouse Phenotypes related to Sarcoma:

45 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.31 BRAF CHEK2 FES FLI1 HRAS JUN
2 immune system MP:0005387 10.29 BRAF CHEK2 FES FLI1 JUN KIT
3 cardiovascular system MP:0005385 10.27 BRAF FES FLI1 HRAS JUN KIT
4 mortality/aging MP:0010768 10.27 BRAF CHEK2 FES FLI1 HRAS JUN
5 hematopoietic system MP:0005397 10.26 BRAF CHEK2 FES FLI1 JUN KIT
6 integument MP:0010771 10.24 BRAF FES HRAS JUN KIT KRAS
7 craniofacial MP:0005382 10.22 BRAF FES HRAS KIT KRAS LYN
8 embryo MP:0005380 10.2 BRAF FLI1 JUN KIT KRAS PIK3CA
9 nervous system MP:0003631 10.18 BRAF CHEK2 FES FLI1 HRAS JUN
10 digestive/alimentary MP:0005381 10.16 BRAF FES HRAS KIT KRAS LYN
11 neoplasm MP:0002006 10.14 BRAF CHEK2 FES FLI1 HRAS KIT
12 liver/biliary system MP:0005370 10.13 BRAF FES FLI1 JUN KIT KRAS
13 muscle MP:0005369 10.03 BRAF FES FLI1 KIT KRAS PIK3CA
14 no phenotypic analysis MP:0003012 9.87 HRAS JUN KIT KRAS PIK3CA RB1
15 respiratory system MP:0005388 9.81 BRAF HRAS JUN KIT KRAS LYN
16 pigmentation MP:0001186 9.73 BRAF KIT KRAS RB1 SRC TP53
17 skeleton MP:0005390 9.7 BRAF FES HRAS JUN KIT KRAS
18 vision/eye MP:0005391 9.28 BRAF FES JUN KIT KRAS PIK3CA
Sources

Drugs & Therapeutics for Sarcoma

About this section

Drugs for Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 599)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lopinavir Approved Phase 4 192725-17-0 92727
2
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
3
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
4
Fosaprepitant Approved Phase 4 172673-20-0 219090
5
Aprepitant Approved, Investigational Phase 4 170729-80-3 151165 6918365
6
Dalteparin Approved Phase 4 9005-49-6
7 Cytochrome P-450 CYP3A Inhibitors Phase 4
8 neurokinin A Phase 4
9 Neurokinin-1 Receptor Antagonists Phase 4
10
Substance P Phase 4 33507-63-0 44359816
11 Heparin, Low-Molecular-Weight Phase 4
12
Meloxicam Approved, Vet_approved Phase 3 71125-38-7 5281106 54677470
13
Irinotecan Approved, Investigational Phase 3 100286-90-6, 97682-44-5 60838
14
Cetuximab Approved Phase 3 205923-56-4 56842117 2333
15
Bortezomib Approved, Investigational Phase 3 179324-69-7 93860 387447
16
Morphine Approved, Investigational Phase 3 57-27-2 5288826
17
Dactinomycin Approved, Investigational Phase 3 50-76-0 2019 457193
18
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
19
Aldesleukin Approved Phase 3 85898-30-2, 110942-02-4
20
Nicotine Approved Phase 3 54-11-5 942 89594
21
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
22
Abacavir Approved, Investigational Phase 2, Phase 3 136470-78-5 65140 441300
23
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
24
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
25
Sulfamethoxazole Approved Phase 3 723-46-6 5329
26
Trimethoprim Approved, Vet_approved Phase 3 738-70-5 5578
27
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
28
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
29
Thioguanine Approved Phase 3 154-42-7 2723601
30
Varenicline Approved, Investigational Phase 3 249296-44-4 5310966
31
Dacarbazine Approved, Investigational Phase 2, Phase 3 4342-03-4 5351166
32
Palbociclib Approved, Investigational Phase 3 571190-30-2 5005498 5330286 11431660
33
Epirubicin Approved Phase 3 56420-45-2 41867
34
Ceritinib Approved Phase 3 1032900-25-6
35 Cranberry Approved, Investigational Phase 3
36 Grape Approved Phase 3
37
Denosumab Approved Phase 3 615258-40-7
38
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
39
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
40
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
41
Daunorubicin Approved Phase 3 20830-81-3 30323
42
Zoledronic Acid Approved Phase 3 118072-93-8 68740
43
Idarubicin Approved Phase 3 58957-92-9 42890
44
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
45
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
46
Cefazolin Approved Phase 3 25953-19-9 33255 656510
47
Efavirenz Approved, Investigational Phase 3 154598-52-4 64139
48
Emtricitabine Approved, Investigational Phase 3 143491-57-0 60877
49
Nevirapine Approved Phase 3 129618-40-2 4463
50
Gemcitabine Approved Phase 3 95058-81-4 60750

Interventional clinical trials:

(show top 50) (show all 1783)
# Name Status NCT ID Phase Drugs
1 EpSSG (European Soft Tissue Sarcoma Study Group) Protocol for Non-Metastatic Rhabdomyosarcoma in Children Unknown status NCT00339118 Phase 4 doxorubicin, cytoxan
2 Optimizing Influenza Vaccination in Surgical Oncology Patients Unknown status NCT01698177 Phase 4
3 A Randomized Comparison of Protease Inhibitor-based Versus Non-nucleoside Reverse Transcriptase Inhibitor-based Antiretroviral Therapy for Initial Treatment of Individuals With AIDS-related Kaposi's Sarcoma in Sub-Saharan Africa Completed NCT00444379 Phase 4 Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir
4 Phase IV Trial to Use Stereotactic Body Radiotherapy for Head and Neck Tumors Completed NCT01344356 Phase 4
5 A Prospective Randomized Trial Comparing the Response of HIV Kaposi's Sarcoma (KS) to HAART Versus the Combination of HAART and Chemotherapy (CXT) Completed NCT00380770 Phase 4 Generic HAART Triomune : d4T, 3TC, NVP;Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV
6 Prospective, Randomized Evaluation of Hyperbaric Oxygen Therapy on Wound Healing Following Management of Soft Tissue Sarcoma With Neo-Adjuvant Radiation and Surgical Resection Recruiting NCT03144206 Phase 4 Hyperbaric oxygen
7 Pharmacologic Interaction Between Ifosfamide and Aprepitant in Treated Patients With Soft Tissue Sarcoma Recruiting NCT03514381 Phase 4 Patients starting a treatment with Doxorubicin and Ifosfamide
8 Quality of Life in Patients With Non-adipocyte Soft Tissue Sarcoma Under Palliative Chemotherapy or Pazopanib — a Randomized, Controlled Trial Recruiting NCT03735758 Phase 4 pazopanib or guideline conform chemotherapy
9 An Open Label, Multicenter, Non-Comparative, Phase IV Study of Panitumumab to Characterize Its Safety, Tolerability and Activity in Indian Subjects With Previously Treated Wild-Type RAS (KRAS and NRAS), Metastatic Colorectal Cancer Recruiting NCT02301962 Phase 4 Panitumumab
10 Tacrolimus for the Treatment of Superficial Kaposiform Hemangioendothelioma and Tufted Angioma: a Single Arm Prospective Study Recruiting NCT04056962 Phase 4 Tacrolimus ointment
11 Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma:A Prospective, Randomized Open Trial Recruiting NCT04077515 Phase 4 Sirolimus(0.8mg/m2);Sirolimus(0.7mg/m2)
12 Low Molecular Weight Heparin Versus Aspirin for Venous Thromboembolism Prophylaxis in Orthopaedic Oncology Enrolling by invitation NCT03244020 Phase 4 Aspirin 325mg;Enoxaparin 40Mg/0.4mL Prefilled Syringe
13 Registry of Retroperitoneal, Abdominal, Pelvic and Truncal Sarcoma Patients Treated With Permanently Implantable LDR CivaSheet® to Evaluate the Safety and Feasibility Over 5 Years Not yet recruiting NCT04033081 Phase 4
14 GCSF Plus Plerixafor as First-line Treatment for Autologous Stem Cells Harvest in Children With Malignant Diseases in Need for High-dose Chemotherapy With Stem Cell Rescue. Not yet recruiting NCT02006225 Phase 4 Plerixafor
15 Phase III Study About the Effects of the Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas Unknown status NCT00162721 Phase 3 doxorubicin, ifosfamide, cisplatin
16 Localized Non-Rhabdomyosarcoma Soft Tissue Sarcomas Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
17 Phase III Study of The Role of Barrier Resection in Local Control in Treatment of Extremity Soft Tissue Sarcomas Unknown status NCT02120768 Phase 3
18 A Registered Randomized, Double-Blind, Placebo-Controlled (2:1), Multi-Centered Clinical Trial of Anlotinib as a Treatment for Soft Tissue Sarcoma Unknown status NCT02449343 Phase 2, Phase 3 Anlotinib;Placebo
19 Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Adriamycin, Bleomycin, and Vincristine (ABV) in the Treatment of Severe AIDS-Related Kaposi's Sarcoma Unknown status NCT00002318 Phase 3 Doxorubicin hydrochloride (liposomal);Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride
20 A Phase III Randomized Study of Preoperative Radiotherapy Plus Surgery Versus Surgery Alone for Patients With Retroperitoneal Sarcoma (RPS) Unknown status NCT01344018 Phase 3
21 EUROPEAN INTERGROUP COOPERATIVE EWING'S SARCOMA STUDY [EICESS 92] Unknown status NCT00002516 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;mesna;vincristine sulfate
22 Intensified Methotrexate, Vinblastine, Doxorubicin and Cisplatin +/-Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma in Patients Without Harvey Nor Kirsten Rat Sarcoma Viral Oncogene Homolog Mutations. Phase II Study Unknown status NCT02818725 Phase 3 Chemotherapy;panitumumab
23 European Ewing Tumour Working Initiative of National Groups Ewing Tumour Studies 1999 (EURO-E.W.I.N.G.99) Unknown status NCT00020566 Phase 3 busulfan;doxorubicin hydrochloride;etoposide;ifosfamide;melphalan;vincristine sulfate
24 Randomized Double-Blind Controlled Phase III Trial of Hyperbaric Oxygen Therapy in Patients Suffering Long-Term Adverse Effects of Radiotherapy for Pelvic Cancer (HOT II) Unknown status NCT01087268 Phase 3
25 A Phase III Randomized Trial of Gemcitabine (NSC# 613327) Plus Docetaxel (NSC# 628503) Followed by Doxorubicin (NSC# 123127) Versus Observation for Uterus-Limited, High-Grade Uterine Leiomyosarcoma Unknown status NCT01533207 Phase 3 Docetaxel;Doxorubicin Hydrochloride;Gemcitabine Hydrochloride
26 A Double-Blind Randomized Placebo Controlled Trial for Prevention of Tuberculosis-Immune Reconstitution Inflammatory Syndrome With Non-Steroid Anti-Inflammatory Drugs (NSAIDs) in HIV-Infected Adults Unknown status NCT02060006 Phase 3 Meloxicam 7.5mg daily for 8 weeks
27 A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary Unknown status NCT00954174 Phase 3 Carboplatin;Ifosfamide;Paclitaxel
28 A Protocol For Nonmetastatic Rhabdomyosarcoma [RMS-2005] Unknown status NCT00379457 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;topotecan hydrochloride;vincristine sulfate;vinorelbine tartrate
29 Prospective and Randomized Study of Fixed Versus Flexible Prophylactic Administration of Granulocyte Colony-Stimulating Factor (G-CSF) in Children With Cancer Unknown status NCT01987596 Phase 3
30 Comparing the Effectiveness of Combined Hyperthermia and External Beam Radiation (EBRT) Versus EBRT Alone in Treating Patients With Painful Bone Metastases Unknown status NCT01842048 Phase 3
31 A Multicenter, Randomized, Open-Label Phase 3 Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Investigator's Choice in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcomas Who Either Relapsed or Were Refractory to Prior Non-Adjuvant Chemotherapy Completed NCT02049905 Phase 3 Aldoxorubicin;Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)
32 Ph III Random Trial of 120-Min Infusion Gemcitabine v. 90-Min Infusion Gemcitabine + Docetaxel in Unresectable Soft Tissue Sarcoma: A Multi-Disciplinary Trial of the North Amer. Sarcoma Study Group of the Connective Tissue Oncology Society Completed NCT00142571 Phase 3 Gemcitabine;Docetaxel
33 A Pivotal Trial to Determine the Efficacy and Safety of AP23573 When Administered as Maintenance Therapy to Patients With Metastatic Soft-Tissue or Bone Sarcomas Completed NCT00538239 Phase 3 ridaforolimus;Placebo
34 Randomized Study Comparing Neoadjuvant Chemotherapy Etoposide + Ifosfamide + Adriamycin (EIA) Combined With Regional Hyperthermia (RHT) Versus Neoadjuvant Chemotherapy Alone in the Treatment of High-Risk Soft Tissue Sarcomas in Adults Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
35 A Phase III Randomized Study of Preoperative Radiation Plus Surgery Versus Surgery Alone for Patients With Retroperitoneal Sarcomas (RPS) Completed NCT00091351 Phase 3
36 A Randomized Phase 3, Multicenter, Open-Label Study Comparing TH-302 in Combination With Doxorubicin vs. Doxorubicin Alone in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma Completed NCT01440088 Phase 3 TH-302 in Combination with Doxorubicin;Doxorubicin
37 A Randomized, Multicenter, Phase III Trial of Trabectedin (Yondelis) Versus Doxorubicin-based Chemotherapy as First-Line Therapy in Patients With Translocation-Related Sarcomas (TRS) Completed NCT00796120 Phase 3 Trabectedin;Doxorubicin;Ifosfamide
38 Phase 3, Open Label, Multi-centre, Randomised Controlled International Study in Ewing Sarcoma Completed NCT00987636 Phase 3 Zoledronic acid;Busulfan;Treosulfan
39 Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754) Completed NCT02180867 Phase 2, Phase 3 Doxorubicin;Doxorubicin Hydrochloride;Ifosfamide;Pazopanib;Pazopanib Hydrochloride
40 A Randomized Double Blind Phase III Trial of Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy Completed NCT00753688 Phase 3 PAZOPANIB;Placebo
41 Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
42 A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma. Completed NCT00002093 Phase 3 Daunorubicin (liposomal);Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride
43 Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma. Completed NCT00002147 Phase 3 Doxorubicin hydrochloride (liposomal)
44 MMT 95 Study For Rhabdomyosarcoma and Other Malignant Soft Tissue Tumors of Childhood Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
45 Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia Administered to Patients With High-Risk Sarcoma Receiving Intensive Chemotherapy (Adriamycin and Ifosfamide (AI)) Completed NCT00038311 Phase 3 PN-152,243)/PN-196,444
46 Double-Blind Randomized Evaluation of Clinical Benefits of DOXIL in Patients With AIDS-Related Kaposi's Sarcoma Treated With DOXIL or DaunoXome Completed NCT00002985 Phase 3 daunorubicin hydrochloride;pegylated liposomal doxorubicin hydrochloride
47 Open Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma Completed NCT00002319 Phase 3 Doxorubicin hydrochloride (liposomal)
48 Randomised Trial of Post-Operative Radiotherapy Given to Adult Patients With Extremity Soft Tissue Sarcoma [VORTEX] Completed NCT00423618 Phase 3
49 METASTASECTOMY AND CHEMOTHERAPY FOR LUNG METASTASES FROM SOFT TISSUE SARCOMA: A RANDOMIZED PHASE III STUDY (AN INTERGROUP STUDY WITH THE SCANDINAVIAN SARCOMA GROUP) Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
50 Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma Completed NCT00002105 Phase 3 Doxorubicin hydrochloride (liposomal);Bleomycin sulfate;Vincristine sulfate

Search NIH Clinical Center for Sarcoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Ifosfamide
Mitoxantrone
Mitoxantrone Hydrochloride
Thiotepa
Sources

Genetic Tests for Sarcoma

About this section

Genetic tests related to Sarcoma:

# Genetic test Affiliating Genes
1 Sarcoma 29
Sources

Anatomical Context for Sarcoma

About this section

MalaCards organs/tissues related to Sarcoma:

40
Bone, Lung, Myeloid, Breast, Liver, Kidney, Uterus
Sources

Publications for Sarcoma

About this section

Articles related to Sarcoma:

(show top 50) (show all 30592)
# Title Authors PMID Year
1
Sarcoma of the cervical spine after radiation treatment for thyroid cancer. 54 61
20375775 2010
2
[A case of undifferentiated (embryonal) liver sarcoma mimicking klatskin tumor in an adult]. 54 61
20168062 2010
3
IGF-1R targeted treatment of sarcoma. 61 54
20036195 2010
4
Claudin-1 is expressed in perineurioma-like low-grade fibromyxoid sarcoma. 54 61
19540561 2009
5
Undifferentiated sarcoma: does it exist? A clinicopathologic study of 7 pediatric cases and review of literature. 54 61
19647855 2009
6
Prognostic significance of phosphorylated FOXO1 expression in soft tissue sarcoma. 61 54
19408047 2009
7
[A sarcoma of the colonic wall with desmin expression]. 61 54
19364593 2009
8
Low-grade fibromyxoid sarcoma versus fibromatosis: a comparative study of clinicopathological and immunohistochemical features. 54 61
19021197 2009
9
Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma. 54 61
18855347 2008
10
Endosialin protein expression and therapeutic target potential in human solid tumors: sarcoma versus carcinoma. 61 54
19010839 2008
11
New targets for therapy of sarcoma. 61 54
18525335 2008
12
Leukemic transformation of Langerhans cell sarcoma. 61 54
18360746 2008
13
Stathmin activity influences sarcoma cell shape, motility, and metastatic potential. 54 61
18305103 2008
14
[Diffuse expression of KIT in a pulmonary artery sarcoma]. 54 61
18516991 2008
15
Differential diagnosis of sarcomatoid mesothelioma from true sarcoma and sarcomatoid carcinoma using immunohistochemistry. 54 61
18199156 2008
16
Immunohistochemical discrimination between the ASPL-TFE3 fusion proteins of alveolar soft part sarcoma. 54 61
18176180 2008
17
Pulmonary artery sarcoma mimicking a pulmonary embolism. 61 54
18453737 2008
18
Ewing sarcoma protein ewsr1 maintains mitotic integrity and proneural cell survival in the zebrafish embryo. 61 54
17912356 2007
19
Standards and novel therapeutic options in the treatment of patients with soft tissue sarcoma. 61 54
18474006 2007
20
Expression of MYCN in pediatric synovial sarcoma. 61 54
17464317 2007
21
High prevalence of p53 exon 4 mutations in soft tissue sarcoma. 61 54
17429838 2007
22
Immunostaining for SYT protein discriminates synovial sarcoma from other soft tissue tumors: analysis of 146 cases. 54 61
17334346 2007
23
Systemic treatment options for patients with refractory adult-type sarcoma beyond anthracyclines. 54 61
17264755 2007
24
Markers of angiogenesis and clinical features in patients with sarcoma. 54 61
17265525 2007
25
Germline mutations of TP53 and BRCA2 genes in breast cancer/sarcoma families. 54 61
17224268 2007
26
Mediastinal follicular dendritic cell sarcoma involving bone marrow: a case report and review of the literature. 61 54
17126255 2006
27
Apoptosis induced by chemotherapeutic agents involves c-Jun N-terminal kinase activation in sarcoma cell lines. 61 54
16705697 2006
28
Immunohistochemical analysis of embryonal sarcoma of the liver. 61 54
16785789 2006
29
Prognostic significance of Wilms tumor gene (WT1) mRNA expression in soft tissue sarcoma. 54 61
16607650 2006
30
Mammary NOS-type sarcoma with CD10 expression: a rare entity with features of myoepithelial differentiation. 61 54
16625090 2006
31
Pulmonary manifestation of a Langerhans cell sarcoma: case report and review of the literature. 54 61
16328350 2006
32
The role of genetic testing in soft tissue sarcoma. 54 61
16359533 2006
33
Autoantibody production from a thymoma and a follicular dendritic cell sarcoma associated with paraneoplastic pemphigus. 54 61
16120143 2005
34
Genetic predictors for drug resistance in soft tissue sarcoma: a review of publications in 2004. 61 54
15933471 2005
35
Efficacy of Wnt-1 monoclonal antibody in sarcoma cells. 61 54
15913453 2005
36
Prognostic importance of vascular endothelial growth factor and its receptors in the uterine sarcoma. 54 61
15823121 2005
37
Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma. 61 54
15631540 2005
38
p27(Kip1)-stathmin interaction influences sarcoma cell migration and invasion. 61 54
15652749 2005
39
Intimal sarcoma of the pulmonary artery: report of an autopsy case. 61 54
16136754 2005
40
Carbonic anhydrase IX as a marker for poor prognosis in soft tissue sarcoma. 54 61
15240538 2004
41
A modified p53 enhances apoptosis in sarcoma cell lines mediated by doxorubicin. 61 54
15026814 2004
42
Familial sarcoma: challenging pedigrees. 54 61
14584079 2003
43
Sarcoma and familial retinoblastoma. 54 61
14516425 2003
44
Fusion of the FUS and BBF2H7 genes in low grade fibromyxoid sarcoma. 54 61
12915480 2003
45
Carcinosarcoma (pure endocrine cell carcinoma with sarcoma components) of the stomach. 54 61
12895235 2003
46
Reduced expression of hMSH2 protein is correlated to poor survival for soft tissue sarcoma patients. 54 61
12712483 2003
47
Classification of clear-cell sarcoma as a subtype of melanoma by genomic profiling. 61 54
12721254 2003
48
Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. 61 54
12610779 2003
49
Immunomic analysis of human sarcoma. 61 54
12601173 2003
50
fau and its ubiquitin-like domain (FUBI) transforms human osteogenic sarcoma (HOS) cells to anchorage-independence. 54 61
12660817 2003
Sources

Variations for Sarcoma

About this section

ClinVar genetic disease variations for Sarcoma:

6 (show all 16) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 CHEK2 NM_007194.4(CHEK2):c.341G>A (p.Trp114Ter)SNV Pathogenic 560005 rs1555927374 22:29121334-29121334 22:28725346-28725346
2 PIK3CA NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys)SNV Pathogenic/Likely pathogenic 13655 rs104886003 3:178936091-178936091 3:179218303-179218303
3 TP53 NM_000546.5(TP53):c.743G>A (p.Arg248Gln)SNV Pathogenic/Likely pathogenic 12356 rs11540652 17:7577538-7577538 17:7674220-7674220
4 TP53 NM_000546.5(TP53):c.460G>A (p.Gly154Ser)SNV Uncertain significance 133284 rs137852789 17:7578470-7578470 17:7675152-7675152
5 APC NM_000038.6(APC):c.449A>G (p.Lys150Arg)SNV Uncertain significance 141928 rs371085910 5:112111352-112111352 5:112775655-112775655
6 TP53 NM_000546.5(TP53):c.886C>T (p.His296Tyr)SNV Uncertain significance 132973 rs672601296 17:7577052-7577052 17:7673734-7673734
7 TP53 NM_000546.5(TP53):c.969G>A (p.Leu323=)SNV Likely benign 132974 rs672601297 17:7576877-7576877 17:7673559-7673559
8 TP53 NM_000546.5(TP53):c.448_459del (p.Thr150_Pro153del)deletion not provided 133282 rs137852790 17:7578471-7578482 17:7675153-7675164
9 TP53 NM_000546.5(TP53):c.450_459del (p.Pro151fs)deletion not provided 133283 rs137852791 17:7578471-7578480 17:7675153-7675162
10 FGFR3 NM_000142.4(FGFR3):c.1887C>T (p.Asn629=)SNV not provided 132957 rs104886004 4:1807828-1807828 4:1806101-1806101
11 FGFR3 NM_000142.4(FGFR3):c.1908C>G (p.Phe636Leu)SNV not provided 132958 rs104886005 4:1807849-1807849 4:1806122-1806122
12 FGFR3 NM_000142.4(FGFR3):c.1935C>T (p.Leu645=)SNV not provided 132959 rs104886006 4:1807876-1807876 4:1806149-1806149
13 PIK3CA NM_006218.2:c.1821+51A>TSNV not provided 132966
14 FGFR3 NM_000142.4(FGFR3):c.2135G>A (p.Arg712His)SNV not provided 132968 rs104886024 4:1808377-1808377 4:1806650-1806650
15 KRAS NM_004985.5(KRAS):c.216G>A (p.Met72Ile)SNV not provided 132970 rs104886028 12:25380242-25380242 12:25227308-25227308
16 KRAS NM_004985.5(KRAS):c.219G>A (p.Arg73=)SNV not provided 132971 rs104886027 12:25380239-25380239 12:25227305-25227305
Sources

Expression for Sarcoma

About this section
Search GEO for disease gene expression data for Sarcoma.
Sources

Pathways for Sarcoma

About this section

Pathways related to Sarcoma according to GeneCards Suite gene sharing:

(show top 50) (show all 153)
# Super pathways Score Top Affiliating Genes
1
ERK Signaling 63
Show member pathways
 13.93 TP53 SRC RB1 KRAS KIT JUN
2
GPCR Pathway 63
Show member pathways
 13.83 TP53 SRC RB1 LYN KRAS KIT
3
TGF-Beta Pathway 63
Show member pathways
 13.65 TP53 SRC PIK3CA KRAS KIT JUN
4
Developmental Biology 65
Show member pathways
 13.63 SRC PIK3CA LYN KRAS KIT JUN
5
Cytokine Signaling in Immune system 65
Show member pathways
 13.49 TP53 SRC PIK3CA LYN KRAS KIT
6
IL-2 Pathway 63
Show member pathways
 13.35 TP53 SRC LYN KRAS JUN HRAS
7
Toll-like Receptor Signaling Pathway 1 36
Show member pathways
 13.24 TP53 SRC RB1 PIK3CA KRAS JUN
8
Phospholipase-C Pathway 63
Show member pathways
 13.2 TP53 SRC LYN KRAS KIT HRAS
9
fMLP Pathway 63
Show member pathways
 13.12 TP53 SRC KRAS JUN HRAS BRAF
10
PI3K-Akt signaling pathway 36
Show member pathways
 13.11 TP53 RB1 PIK3CA KRAS KIT HRAS
11
TNFR1 Pathway 63
Show member pathways
 13.09 TP53 SRC RB1 PIK3CA KRAS JUN
12
TCR Signaling (Qiagen) 63
Show member pathways
 13.06 TP53 SRC LYN KRAS JUN HRAS
13
Regulation of lipid metabolism Insulin signaling-generic cascades 22
Show member pathways
 13.03 SRC PIK3CA KRAS JUN HRAS BRAF
14
Focal Adhesion 1 36
Show member pathways
 13.03 SRC RB1 PIK3CA KRAS JUN HRAS
15
CCR5 Pathway in Macrophages 63
Show member pathways
 13.02 SRC PIK3CA LYN KRAS JUN HRAS
16
Human cytomegalovirus infection 36
Show member pathways
 13.02 TP53 SRC RB1 PIK3CA LYN KRAS
17
NFAT and Cardiac Hypertrophy 63
Show member pathways
 12.99 SRC PIK3CA KRAS JUN HRAS BRAF
18
MAPK-Erk Pathway 66
Show member pathways
 12.97 SRC PIK3CA LYN KRAS HRAS BRAF
19
Pathways in cancer 36
12.94 TP53 RB1 PIK3CA KRAS KIT JUN
20
Measles 36
Show member pathways
 12.92 TP53 RB1 PIK3CA LYN JUN
21
Apoptosis Modulation and Signaling 1
Show member pathways
 12.91 TP53 PIK3CA KRAS JUN HRAS
22
Beta-Adrenergic Signaling 63
Show member pathways
 12.91 SRC KRAS JUN HRAS BRAF
23
MAPK signaling pathway 1 36
12.9 TP53 KRAS KIT JUN HRAS BRAF
24
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 64
Show member pathways
 12.88 PIK3CA KRAS JUN HRAS BRAF
25
Ras signaling pathway 36
Show member pathways
 12.87 SRC PIK3CA KRAS KIT HRAS BRAF
26
Development Angiotensin activation of ERK 22
Show member pathways
 12.84 SRC PIK3CA LYN KRAS KIT JUN
27
Downstream signaling events of B Cell Receptor (BCR) 65
Show member pathways
 12.83 TP53 SRC PIK3CA LYN KRAS KIT
28
Gastric cancer 36
Show member pathways
 12.82 TP53 RB1 PIK3CA KRAS KIT JUN
29
4-1BB Pathway 63
Show member pathways
 12.81 TP53 RB1 KRAS JUN HRAS BRAF
30
Development HGF signaling pathway 22
Show member pathways
 12.81 TP53 SRC PIK3CA KRAS JUN HRAS
31
Relaxin signaling pathway 36
Show member pathways
 12.8 SRC PIK3CA KRAS JUN HRAS
32
Endometrial cancer 36
Show member pathways
 12.8 TP53 SRC RB1 PIK3CA KRAS KIT
33
DREAM Repression and Dynorphin Expression 63
Show member pathways
 12.79 SRC RB1 KRAS JUN HRAS
34
Development Endothelin-1/EDNRA signaling 22
Show member pathways
 12.77 SRC PIK3CA KRAS JUN HRAS
35
Regulation of actin cytoskeleton 1 36
12.76 SRC PIK3CA KRAS HRAS BRAF
36
Immune response IL-23 signaling pathway 22
Show member pathways
 12.73 TP53 SRC PIK3CA KRAS HRAS FES
37
Immune response Fc epsilon RI pathway 22
Show member pathways
 12.73 SRC PIK3CA LYN KRAS JUN HRAS
38
ErbB signaling pathway 1 36
Show member pathways
 12.72 TP53 SRC PIK3CA KRAS JUN HRAS
39
Glioma 36
Show member pathways
 12.72 TP53 SRC RB1 PIK3CA KRAS JUN
40
Negative regulation of FGFR3 signaling 65
Show member pathways
 12.69 SRC PIK3CA KRAS HRAS BRAF
41
Immune response Role of DAP12 receptors in NK cells 22
Show member pathways
 12.65 PIK3CA KRAS JUN HRAS BRAF
42
mTOR signaling pathway (KEGG) 36
Show member pathways
 12.64 TP53 PIK3CA KRAS HRAS BRAF
43
Oxytocin signaling pathway 36
Show member pathways
 12.62 SRC KRAS JUN HRAS BRAF
44
Prolactin Signaling Pathway 1 36
Show member pathways
 12.62 SRC PIK3CA KRAS JUN HRAS
45
Development ERBB-family signaling 22
Show member pathways
 12.58 TP53 SRC PIK3CA KRAS JUN HRAS
46
Apoptosis Pathway 70
Show member pathways
 12.57 TP53 PIK3CA KRAS JUN HRAS CHEK2
47
RANK Signaling in Osteoclasts 63
Show member pathways
 12.56 SRC LYN KRAS JUN HRAS BRAF
48
VEGF Pathway (Qiagen) 65
Show member pathways
 12.55 SRC PIK3CA KRAS JUN HRAS
49
Phospholipase D signaling pathway 36
Show member pathways
 12.55 PIK3CA KRAS KIT JUN HRAS
50
Development FGFR signaling pathway 22
Show member pathways
 12.55 SRC PIK3CA KRAS